Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
Name (Synonyms) | Correlation | |
---|---|---|
drug1160 | Electro impedance tomography Wiki | 0.21 |
drug1396 | Group B Control Wiki | 0.21 |
drug278 | Artemesia annua Wiki | 0.21 |
Name (Synonyms) | Correlation | |
---|---|---|
drug1392 | Group A HCQ Wiki | 0.21 |
drug1120 | ELISPOT Wiki | 0.21 |
drug700 | Capnography Wiki | 0.21 |
drug1661 | Inhaled budesonide Wiki | 0.21 |
drug1841 | Lopinavir Wiki | 0.21 |
drug18 | 0.9%NaCl Wiki | 0.21 |
drug2723 | Quasistatic pressure-volume curve Wiki | 0.21 |
drug2197 | Nitazoxanide with ivermectin Wiki | 0.21 |
drug2323 | Online questionnaire and interviews Wiki | 0.21 |
drug3999 | personal protective Measures Wiki | 0.21 |
drug2852 | Respiratory monitoring Wiki | 0.21 |
drug2876 | Ritonavir Wiki | 0.21 |
drug283 | Arterial blood gas Wiki | 0.21 |
drug1461 | High volume evacuation (HVE) Wiki | 0.21 |
drug2709 | QUANTIFERON Wiki | 0.21 |
drug284 | Artesunate Wiki | 0.21 |
drug1996 | Melatonin 2mg Wiki | 0.21 |
drug1263 | Extraoral vacuum aspirator (EVA) Wiki | 0.21 |
drug1504 | Hydrogen Peroxide Wiki | 0.21 |
drug2853 | Respiratory muscles ultrasound Wiki | 0.21 |
drug1085 | Doxycycline Hcl Wiki | 0.21 |
drug3993 | oxyhydrogen Wiki | 0.21 |
drug2054 | Mindfulness training (MT) Connect Wiki | 0.21 |
drug3715 | a specifically designed self-administered questionnaire Wiki | 0.21 |
drug1899 | Lung CT Wiki | 0.21 |
drug3774 | captopril 25mg Wiki | 0.21 |
drug1258 | External evacuation device (EED) Wiki | 0.21 |
drug3221 | Standard treatment for COVID-19 Wiki | 0.21 |
drug1008 | Deferoxamine Wiki | 0.15 |
drug890 | Convalescent Plasma Transfusion Wiki | 0.15 |
drug761 | Chloroquine or Hydroxychloroquine Wiki | 0.12 |
drug3043 | Selinexor Wiki | 0.12 |
drug1672 | Interferon Beta-1A Wiki | 0.10 |
drug366 | BCG Vaccine Wiki | 0.10 |
drug2354 | Oxygen Wiki | 0.10 |
drug1507 | Hydroxychloroquine Wiki | 0.10 |
drug769 | Cholecalciferol Wiki | 0.09 |
drug3871 | hydroxychloroquine Wiki | 0.09 |
drug1084 | Doxycycline Wiki | 0.09 |
drug2490 | Placebo Wiki | 0.09 |
drug965 | DAS181 Wiki | 0.09 |
drug3633 | Vitamin D3 Wiki | 0.09 |
drug3697 | Zinc Wiki | 0.07 |
drug1861 | Losartan Wiki | 0.07 |
drug341 | Azithromycin Wiki | 0.07 |
drug686 | Camostat Mesilate Wiki | 0.07 |
drug3628 | Vitamin C Wiki | 0.05 |
drug2557 | Placebo oral tablet Wiki | 0.04 |
drug2827 | Remdesivir Wiki | 0.04 |
drug3191 | Standard of Care Wiki | 0.03 |
Name (Synonyms) | Correlation | |
---|---|---|
D045169 | Severe Acute Respiratory Syndrome NIH | 0.17 |
D018352 | Coronavirus Infections NIH | 0.14 |
D007239 | Infection NIH | 0.11 |
Name (Synonyms) | Correlation | |
---|---|---|
D003141 | Communicable Diseases NIH | 0.07 |
D007251 | Influenza, Human NIH | 0.06 |
D055370 | Lung Injury NIH | 0.04 |
D055371 | Acute Lung Injury NIH | 0.03 |
D011014 | Pneumonia NIH | 0.03 |
D012127 | Respiratory Distress Syndrome, Newborn NIH | 0.02 |
D012128 | Respiratory Distress Syndrome, Adult NIH | 0.02 |
Navigate: Correlations HPO
There are 23 clinical trials
Efficacy of Ivermectin and Nitazoxanide in COVID-19 treatment
Description: The number of patients with improvement or death
Measure: Number of patients with improvement or died Time: 1 monthAt present, there are no specific treatments for COVID-19. WHO recommends four treatments for COVID 19 with drugs i.eRemdesivir, Lopinavir/ ritonavir, Lopinavir/ ritonavir with interferon beta -1a, and chloroquine or hydroxychloroquine. Currently, there are several ongoing clinical trials evaluating potential treatments. Recently, LeonCaly reported that Ivermectin, an FDA-approved anti-parasitic previously shown to have broad-spectrum anti-viral activity in vitro, is an inhibitor of the causative virus (SARS-CoV-2), with a single addition to Vero-hSLAM cells 2 hours post infection with SARSCoV-2 able to effect about 5000-fold reduction in viral RNA at 48 h. Ivermectin therefore warrant further investigation for possible benefits in humans. The study rationale is to understand the effect of the drug on eradication of virus.
Description: Test for virus at 1, 3 & 5 days from beginning of trial drug started for the patient in the hospital
Measure: effect of Ivermectin on eradication of virus. Time: 3 monthsThis is a multi-arm, phase II trial for rapid efficacy and toxicity assessment of multiple therapies immediately after COVID19 positive testing in high-risk individuals. Therapies include stand-alone or combination treatment with hydroxychloroquine, azithromycin, ivermectin, or camostat mesilate, artemesia annua. The hypothesis of this study is that the addition of agents that inhibit viral entry or replication of SARS-CoV-2 virus replication in will be devoid of additional moderate to severe toxicities, will prevent clinical deterioration, and will improve viral clearance in high risk individuals.
Description: Proportion of patients experiencing clinical deterioration. Clinical deterioration is defined as a less than a 2-point change from the initial COVID 7-Point Ordinal Outcomes Scale within 14 days from the study start. This scale ranges from 1-7. Lower scores indicate worse outcomes (death); higher scores indicate fewer symptoms and better outcomes.
Measure: Clinical Deterioration Time: 14 daysDescription: The change in (clearance of) viral RNA will be measured by PCR testing at days 1, 14, 28, and 40 days.
Measure: Change in Viral Load Time: 40 daysDescription: Percentage of patients that experience severe respiratory or other organ failure.
Measure: Rate of Organ Failure Time: 28 daysDescription: Percentage of patients requiring ICU admission or ventilation.
Measure: Progression to ICU Care or Ventilation Time: 28 daysDescription: Clinical status will be assessed using the COVID 7-Point Ordinal Outcomes Scale. This scale ranges from 1-7. Lower scores indicate worse outcomes; higher scores indicate fewer symptoms and better outcomes.
Measure: Change in Clinical Status Time: 14 daysDescription: Percentage of patients who have died by day 14.
Measure: Mortality Time: 14 daysDescription: Percentage of patients experiencing severe adverse events, defined as grade 3 non-hematologic or greater by DMID Toxicity Scale for Determining Severity of Adverse Events.
Measure: Rate of severe adverse events Time: 14 daysDescription: Number of days patients do not require oxygen supplementation.
Measure: Oxygen-free days Time: 28 daysDescription: Number of days patients do not require mechanical ventilation.
Measure: Ventilator-free days Time: 28 daysDescription: Number of days patients do not require vasopressor treatment.
Measure: Vasopressor-free days Time: 28 daysDescription: Number of days patients do not require ICU services.
Measure: ICU-free days Time: 28 daysDescription: Number of days patients do not require hospitalization.
Measure: Hospital-free days Time: 28 daysDescription: Proportion of patients meeting Hy's law criteria.
Measure: Patients meeting Hy's Law criteria Time: 28 daysDescription: Proportion of patients with changes in the following liver function tests: Any ALT or AST ≥ 5 x ULN; any AST or ALT ≥ 3 x ULN together with the appearance of fatigue, nausea, vomiting, right upper quadrant pain or tenderness, fever, rash and/or eosinophilia (eosinophil percent or count above the ULN); Persistent ALT ≥ 3 x ULN for a period of more than 4 weeks
Measure: Liver Function Time: 28 daysDescription: Proportion of patients with significant changes in ECG findings, including heart rate, ECG intervals (PR, QTcB, QTcF), conduction changes, or abnormalities including severe QTc prolongation of > 500 ms.
Measure: Heart Function Time: 28 daysWe have to be aware of the challenge and concerns brought by 2019-nCoV to our healthcare workers. Front-line healthcare workers can become infected in the management of patients with COVID-19; the high viral load in the atmosphere, and infected medical equipment are sources for the spread of SARS-CoV-2. If prevention and control measures are not in place, these healthcare workers are at great risk of infection and become the inadvertent carriers to patients who are in hospital for other diseases. Nowadays a question that has not yet been clarified by science has been arises: is hydroxychloroquine associated with zinc compared to ivermectin associated with zinc effective as a prophylaxis for asymptomatic professionals involved in the treatment of suspected or confirmed case of COVID-19?
Description: Proportion of participants in whom there was a a positivity for SARS-CoV-2 through specific examination (RT-PCR) or by serology for antibodies specific (IgM and IgG), corroborated or not with clinical finding of COVID-19, defined as the occurrence of signs and symptoms suggestive of this disease.
Measure: Proportion of participants in whom there was a positivity for SARS-CoV-2. Time: Post-intervention at day 52Description: Proportion of participants who developed mild, moderate, or severe forms of COVID-19.
Measure: Participants who developed mild, moderate, or severe forms of COVID-19. Time: Post-intervention at day 52.Description: Measurement of the QT interval through electrocardiogram evaluation.
Measure: Measurement of the QT interval. Time: Baseline, 3, 15 and 45 days post-intervention.Description: Proportion of participants who evolved with widening of the corrected QT interval or with changes in heart rate on the ECG.
Measure: Widening of the corrected QT interval or with changes in heart rate on the ECG. Time: Day 52.Description: Comparison of baseline (visit 0) and final (visit 5) values of hematological and biochemical parameters.
Measure: Comparison of hematological and biochemical parameters. Time: Day 52.Description: Proportion of occurrence of adverse events reported by participants or verified by the attending physician, or even observed in laboratory tests.
Measure: Occurrence of adverse events. Time: Post-intervention at day 52.Description: Severity of symptoms of COVID-19 measured by a visual analog scale (VAS), with scores ranging from zero to 10, where zero represents the absence of the symptom and 10 corresponds to the most intense manifestation of symptoms (severe dyspnoea).
Measure: Assessment of COVID-19 symptom severity. Time: Post-intervention at day 52.Description: Proportion of participants who discontinue study intervention,
Measure: Proportion of participants who discontinue study intervention. Time: Post-intervention at day 52.Description: Proportion of participants who required hospital care.
Measure: Proportion of participants who required hospital care. Time: Post-intervention at day 52.Description: Proportion of participants who required mechanical ventilation.
Measure: Proportion of participants who required mechanical ventilation. Time: Post-intervention at day 52.SAINT is a double-blind, randomized controlled trial with two parallel groups that evaluates the efficacy of ivermectin in reducing nasal viral carriage at seven days after treatment in SARS-CoV-2 infected patients who are at low risk of progression to severe disease. The trial is currently planned at a single center in Navarra.
Description: Proportion of patients with a positive SARS-CoV-2 PCR from a nasopharyngeal swab at day 7 post-treatment. PCRs were performed using two target genes (E and N).
Measure: Proportion of Patients With a Positive SARS-CoV-2 PCR Time: 7 days post-treatmentDescription: Quantitative and semi-quantitative PCR in nasopharyngeal swab. PCRs were performed using two target genes (E and N).
Measure: Median Viral Load Time: Baseline and on days 4, 7, 14 and 21Description: Proportion of patients with fever and cough
Measure: Fever and Cough Progression Time: Days 4, 7, 14 and 21Description: Proportion of participants with positive IgG at day 21
Measure: Seroconversion at Day 21 Time: Up to and including day 21Description: Proportion of drug-related adverse events
Measure: Proportion of Drug-related Adverse Events Time: 7 days post treatmentDescription: Levels in median fluorescence intensity (MFI) of IgG, IgM and IgA against the receptor-binding domain of the spike glycoprotein of SARS-CoV-2 in plasma, measured by a Luminex assay. [Results not yet available]
Measure: Levels of IgG, IgM and IgA Time: Up to and including day 28Description: Frequency (% over total PBMC) of innate immune cells (myeloid and plasmacytoid dendritic cells, NK cell, classical, intermediate and pro-inflammatory macrophages) measured in cryopreserved PBMC by flow cytometry. [Results not yet available]
Measure: Frequency of Innate Immune Cells Time: Up to and including day 7Description: Frequency of CD4+ T and CD8+ T cells (% over total CD4+T and CD8+ T) expressing any functional marker upon in vitro stimulation of PBMC with SARS-CoV-2 peptides, measured by flow cytometry. [Results not yet available]
Measure: Frequency SARS-CoV-2-specific CD4+ T and and CD8+ T Cells Time: Up to and including day 7Description: Concentration (all in pg/mL) of epidermal growth factor (EGF), fibroblast growth factor (FGF), granulocyte colony-stimulating factor (G-CSF), granulocyte-macrophage colony-stimulating factor (GM-CSF), hepatocyte growth factor (HGF), vascular endothelial growth factor (VEGF), tumour necrosis factor (TNF), interferon (IFN)-α, IFN-γ, interleukin (IL)-1RA, IL-1β, IL-2, IL-2R, IL-4, IL-5, IL-6, IL-7, IL-8, IL-10, IL-12(p40/p70), IL-13, IL-15, IL-17, IFN-γ induced protein (IP-10), monocyte chemoattractant protein (MCP-1), monokine induced by IFN-γ (MIG), macrophage inflammatory protein (MIP)-1α, MIP-1β in plasma measured by a Luminex assay using a commercially available kit (Cytokine Human Magnetic 30-Plex Panel from ThermoFisher). [Results not yet available]
Measure: Results From Cytokine Human Magnetic 30-Plex Panel Time: Up to and including day 28Background: In December 2019, patients with pneumonia secondary to a new subtype of Coronavirus (COVID-19) were identified in China. In a few weeks the virus spread and cases started practically all over the world. In February 2020, the WHO declared a pandemic. Severe symptoms have been found in patients mainly with comorbidities and over 50 years of age. At this time there is no proven therapeutic alternative. In vitro studies and observational experiences showed that antimalarial drugs (Chloroquine and hydroxychloroquine) had antiviral activity and increased viral clearance. Ivermectin, on the other hand, has been shown in vitro to reduce viral replication and in an observational cohort, greater viral clearance with promising clinical results. So far there is no standard of treatment and clinical trials are needed to find effective treatment alternatives. Objective: To evaluate the safety and efficacy of treatment with hydroxychloroquine and ivermectin for serious COVID-19 infections in no critical hospitalized patients. Material and methods: Randomized controlled trial of patients diagnosed with respiratory infection by COVID-19, who present criteria for hospitalization. Randomization will be performed to receive hydroxychloroquine at a dose of 400 mg every 12 hours for one day and then 200 mg every 12 hours, to complete a 5-day treatment schedule. Group 2: Ivermectin 12 mg every 24 hours for one day (less than 80 kg) or Ivermectin 18 mg every 24 hours for one day (greater than 80 kg) + placebo until the fifth day. Group 3: Placebo. Prior to randomization, the risk of cardiovascular complications determined by corrected QT interval, related to hydroxychloroquine intake will be assessed. If the patient is at high risk, the allocation will be to ivermectin only or to placebo in an independent randomization, if the risk is low, any of the three groups could be assigned. Outcomes: The primary outcome will be discharge from hospital for improvement. The safety outcomes will be requirement of mechanical intubation, septic shock or death. Viral clearance will also be evaluated by means of PCR, which will be taken on the 5th day after admission, day 14 and 21.
Description: Days from admission as a suspected case of COVID with hospitalization criteria until discharge
Measure: Mean days of hospital stay Time: Three monthsDescription: Respiratory deterioration defined by respiratory rate > 25 per minute, requirement of high oxygen supply (FiO2 > 80% ) to maintain oxygen saturation > 90 %, invasive mechanical ventilation or dead.
Measure: Rate of Respiratory deterioration, requirement of invasive mechanical ventilation or dead Time: Three monthsDescription: Daily delta of oxygenation index during the hospitalization
Measure: Mean of oxygenation index delta Time: Three monthsDescription: Mean time to viral negativization of RT-qPCR SARS-CoV-2. Pre Specified time: 5, 14, 21 and 28 days after the first positive PCR.
Measure: Mean time to viral PCR negativization Time: 5, 14, 21 and 28 days after the first positive PCRAs the world faces COVID-19, the search for effective treatments against the disease and its complications has turned its gaze to drugs that are classically used in other infectious diseases. Some drugs are being examined for the recent evidence on its effects on viral replication and inflammation, one is Azithromycin, used to treat a wide variety of bacterial infections, Ivermectin, an anti-parasitic drug and the other is Cholecalciferol to increase serum concentration of 25-hydroxyvitamin D.
Description: Test for virus at day 1 and 14 from beginning of trial drug started
Measure: Viral clearance Time: 14 daysDescription: The duration of symptoms in days
Measure: Symptoms duration Time: 14 daysDescription: oxygen saturation
Measure: SpO2 Time: 14 daysDescription: Oxygen Saturation (SpO2)/Fraction of Inspired Oxygen (FiO2) Ratio
Measure: SpO2/FiO2 Time: 14 daysEfficacy of Ivermectin and Doxycycline in COVID-19 treatment
Description: The number of patients with improvement or mortality
Measure: The number of patients with improvement or mortality Time: 1 monthThis study aims to evaluate the efficacy, safety and tolerability of Ivermectin in patients with mild SARS-CoV-2 infection, in the rate of progression to severe 2019 novel coronavirus disease (COVID-19). The primary efficacy endpoint is the proportion of participants with a disease control status defined as no progression of severe disease Hypothesis (H0): There is no difference between group A (ivermectin + paracetamol) and group B (ivermectin + paracetamol) in terms of the primary endpoint on day 14.
Description: The subject is considered to have progressed to severe illness when one or more of the following criteria are present: Breathing difficulty (≥30 breaths per minute); Resting oxygen saturation ≤93%; Severe complications such as: respiratory failure, need for mechanical ventilation, septic shock, non-respiratory organic failure.
Measure: Participants with a disease control status defined as no disease progression to severe. Time: 14 daysas Egypt suffered a lot during the pandemic of COVID 19 with limited drug choices, many of the patients could not acheive viral clearence with the standard module of care teh idea of introduction of new medications in the treatment protocol of COVID 19 managment. Ivermectin had shown a promising results in vitro studies and in limited in vivo studies. this clinical trial may open a new hope for COVID 19 patients as a new and cheap line of treatment
Description: the role of ivermectin in the cure of COVID 19 patients
Measure: to evaluate the role of Ivermectin as a line of treatment for COVID 19 Time: 2 monthsDescription: to compare the results of ivermectin with the standard care
Measure: To asses the rate of viral clearance in comparison to other treatment protocols. Time: 2 monthsIn December 2019, a group of patients with pneumonia of unknown cause was linked to a wholesale seafood market in Wuhan, China. The genetic analysis of samples from the lower respiratory tract of these patients indicated a new coronavirus as the causative agent, which was named SARS-CoV-2. The virus spread rapidly to more than 45 countries, including Brazil, causing an international alarm. However, in spite of its epidemiological magnitude, so far, there is no antiviral treatment or vaccine approved for the treatment of this infection. With about 15% to 20% of SARS-CoV-2 patients suffering from serious illnesses and overburdened hospitals, therapeutic options are desperately needed. So, instead of creating compounds from scratch that can take years to develop and test, researchers and public health agencies have sought to redirect drugs already approved for other diseases and known to be widely safe. In this context, the analysis of the international literature shows the existence of an in vitro antiviral activity of ivermectin against SARS-CoV-2. However, there are no studies that have evaluated its clinical effectiveness in patients diagnosed with SARS-CoV-2 infection. Therefore, and considering this knowledge gap, the present study aims to determine the clinical efficacy and safety of different doses of ivermectin in patients diagnosed with SARS-CoV-2 infection.
Description: Time to undetectable SARS-CoV-2 viral load in the nasopharyngeal swab after Intervention Initiation.
Measure: Time to undetectable SARS-CoV-2 viral load in the nasopharyngeal swab. Time: 7 days following interventionDescription: Viral load variation in the nasopharyngeal swab during treatment.
Measure: Viral load variation in the nasopharyngeal swab. Time: 7 days following intervention.Description: Variation of serum lymphocyte counts during treatment.
Measure: Time to undetectable SARS-CoV-2 viral load in the nasopharyngeal swab. Time: 7 days following intervention.Description: Proportion of patients with undetectable SARS-CoV-2 viral load in the nasopharyngeal swab at the end of follow-up.
Measure: Proportion of patients with undetectable SARS-CoV-2 viral load in the nasopharyngeal swab. Time: 7 after intervention.Description: Proportion of patients with clinical improvement, defined as the time to normalize fever, respiratory rate and oxygen saturation and cough relief at the end of follow-up.
Measure: Proportion of patients with clinical improvement. Time: 7 after intervention.Prospective, multi-centre, randomized, double-blind trial to assess efficacy and safety of ivermectin for the treatment of initial infection with SARS-CoV2 infection. Study arms: A) placebo B) ivermectin 600 μg/kg daily for 5 consecutive days (I_600) + placebo. C) ivermectin 1200 μg/kg daily at empty stomach with water for 5 consecutive days (I_1200). Patients will be randomized at emergency room of hospitals as well as at outpatient ambulatory care as well as at home, according to routine procedures of recruiting centres. In arm A and B, the number of placebo tablets to be administered will be calculated by the study dedicated pharmacist considering the number of tablets that should be taken in case a patient with the same weight is assigned to arm C.
Description: Number of serious adverse drug reaction
Measure: SADR Time: 14 daysDescription: Quantitative viral load as measured by quantitative, digital droplet PCR.
Measure: Viral load Time: Assessed at day 7Description: 1. Trend over time of quantitative viral load at Day 7 and 14 as measured by quantitative, digital droplet PCR.
Measure: Trend viral load Time: Days 7 and 14 from baselineDescription: Time to clinical resolution (for symptomatic patients).
Measure: Clinical resolution Time: Assessed on Day 30Description: Time from diagnosis to documented viral clearance
Measure: Viral clearance Time: assessed on days 14 and 30Description: Proportion of patients with virological clearance
Measure: Virological clearance Time: Assessed at day 14 and 30Description: rate of hospitalization
Measure: hospitalization rate Time: Day 30Description: COVID-19 Severity Score (Coronavirus Diseases 19 Severity Score) - min value 1 ("no limitation of activities), max value 8 ("death"). Higher scores mean worse outcome
Measure: Severity score Time: Assessed at Day 14 and Day 30confirmed cases with COVID-19 will receive ivermectin as a therapeutic option as well as standard of care treatment and will be compared to those that will receive only standard of care ttt
Description: duration from day 1 symptoms till 3 days without symptoms
Measure: time to be symptoms free Time: within 21 days after enrollmentDescription: need hospital admission
Measure: hospitalization Time: within 21 days after enrollementDescription: need mechanical ventilation
Measure: Mechanical ventilation Time: within 21 days after enrollementDescription: days spent in hospital
Measure: length of stay Time: within one month days after enrollementDescription: survived or died
Measure: mortality Time: within one month days after enrollementIvermectin plus losartan as prophilaxy to severe events in patients with cancer with recent diagnosis of COVID-19
Description: Incidence of severe complications due COVID-19 infection defined as need for ICU admission, need for mechanical ventilation, or death
Measure: Incidence of severe complications due COVID-19 infection Time: 28 daysDescription: Severe Acute Respiratory Syndrome defined as oxygen saturation less than 93%
Measure: Incidence of Severe Acute Respiratory Syndrome Time: 28 daysDescription: Severe Acute Respiratory Syndrome defined as respiratory rate higher than 24 incursion per minute
Measure: Incidence of Severe Acute Respiratory Syndrome Time: 28 daysDescription: Incidence of hepatic toxicity (elevation of ALT, AST above the upper limit of normal, measured by U/L)
Measure: Adverse events Time: 28 daysDescription: Incidence of hepatic toxicity (elevation of bilirubin above the upper limit of normal, measured by mg/dL)
Measure: Adverse events Time: 28 daysDescription: Incidence of renal toxicity (elevation of serum creatinine levels above the upper limit of normal, measured by mg/dL)
Measure: Adverse events Time: 28 daysDescription: Incidence of symptomatic postural hypotension, diagnosed by clinical assessment of reduction of > 20 mmHG of arterial systolic pressure after measurement in prone position and orthostatic position.
Measure: Adverse events Time: 28 daysDescription: Death of any cause since protocol enrollment
Measure: Overall survival Time: 28 daysOn 11th of March 2020, WHO characterized COVID-19 infection as a Pandemic. After the COVID-19 infection is declared as a Pandemic there was an outburst regarding COVID-19 Research. The Research interest led to registration of Interventional and Observational studies world wide. There are constant efforts by Health care workers to seek information regarding the Interventional and Observational studies which can help in decision making regarding effective handling of COVID-19 infected patients. It is also important to track on the happenings in various frontiers of COVID-19 Research in view of historical interest and clinical relevance. This Observational Cross sectional study aims to explore the completed Researches in WHO-compliant registries to understand the trends of COVID-19 Research. This study aims to get a birds eye view of ongoing COVID-19 Research scenario worldwide. This study results can directly benefit the worldwide Academicians and Health Care Professionals to understand the ongoing COVID-19 Research trends.
Description: To understand the geographical distribution of the interventional studies after 11th of March 2020.
Measure: Geographical distribution of the interventional studies after 11th of March 2020. Time: 15th of August 2020Description: To understand the geographical distribution of the Observational studies after 11th of March 2020.
Measure: Geographical distribution of the Observational studies after 11th of March 2020. Time: 15th of August 2020Description: To understand the monthly Research study completion rate as per geographic distribution of the Research.
Measure: Monthly Research study completion rate as per geographic distribution of the Research. Time: 15th of August 2020Description: To understand the statistical correlation of the interventional studies Research with developed, developing and under developed countries.
Measure: Statistical correlation of the interventional studies Research with developed, developing and under developed countries. Time: 15th of August 2020Description: To understand the statistical correlation of the observational studies Research with developed, developing and under developed countries.
Measure: Statistical correlation of the observational studies Research with developed, developing and under developed countries. Time: 15th of August 2020Description: To understand the statistical correlation of the Drug based interventional studies Research with developed, developing and under developed countries.
Measure: Statistical correlation of the Drug based interventional studies Research with developed, developing and under developed countries. Time: 15th of August 2020Description: To understand the statistical correlation of the Diagnostic test based interventional studies Research with developed, developing and under developed countries.
Measure: Statistical correlation of the Diagnostic test based interventional studies Research with developed, developing and under developed countries. Time: 15th of August 2020Description: To understand the statistical correlation of the Device based interventional studies Research with developed, developing and under developed countries.
Measure: Statistical correlation of the Device based interventional studies Research with developed, developing and under developed countries. Time: 15th of August 2020In this trial patients will be treated with either a combination of therapies to treat COVID-19 or a placebo. Treatment will last 10 days, and patients will be followed for 6 months.
Description: Time to negative RT-PRC result indicating that patient is no longer infective
Measure: Time to Non-Infectivity by RT-PCR Time: 6 monthsDescription: Time to reduced symptoms in each treatment group as indicated by NEWS scores, which rate patient status based on a zero to three scale for 8 parameters. These values are added up to create the NEWS score. The lower the NEWS score, the better the patient's clinical condition. Zero is the lowest possible score, whereas 7 or greater represents a high degree of clinical risk.
Measure: Time to Symptom progression in days as measured by NEWS scoring system (National Early Warning Score) Time: 6 monthsDescription: Time to reduced symptoms in each treatment group as indicated by NEWS scores, which rate patient status based on a zero to three scale for 8 parameters. These values are added up to create the NEWS score. The lower the NEWS score, the better the patient's clinical condition. Zero is the lowest possible score, whereas 7 or greater represents a high degree of clinical risk.
Measure: Time to Symptom improvement as measured by NEWS scoring system (National Early Warning Score) Time: 6 monthsDescription: Patients will have serum stored for titer testing to compare antibody levels over time
Measure: Efficacy of Treatment as measured by Titer Time: 6 monthsDescription: Number of patients testing negative for SARS-CoV-2 by RT-PCR after 10 days of treatment
Measure: Efficacy of Treatment as measured by RT-PCR Time: 10 daysDescription: Blood D-Dimer levels
Measure: Safety of Treatment as Measured by D-Dimer Time: 6 MonthsDescription: Blood Pro-Calcitonin levels
Measure: Safety of Treatment as Measured by Pro-Calcitonin Time: 6 MonthsDescription: Blood CRP levels
Measure: Safety of Treatment as Measured by C-Reactive Protein Time: 6 MonthsDescription: Blood ferritin levels
Measure: Safety of Treatment as Measured by Ferritin Time: 6 MonthsDescription: Blood enzyme levels
Measure: Safety of Treatment as Measured by Liver Enzymes Time: 6 MonthsDescription: CBC
Measure: Safety of Treatment as Measured by Complete Blood Count Time: 6 MonthsDescription: Blood electrolytes
Measure: Safety of Treatment as Measured by Electrolyte Levels Time: 6 MonthsDescription: Presence or absence of Grade 3 or high treatment related adverse events
Measure: Safety of Treatment as Measured by Treatment Related Adverse Events Time: 6 monthsIt will be performed a randomized, multicenter, triple-masked, placebo-controlled clinical experiment to determine the effectiveness and safety of the administration to of ivermectin at a dose of 200 mcg/kg once a week for 7 weeks in a prophylactic treatment against SARS COV-2 infection in 550 Colombian health workers during the COVID-19 pandemic.
Description: Development of of the disease according to the definitions of cases found in the guidelines from the Colombian National Institute of Health
Measure: Clinical development of covid-19 disease during the intervention period Time: 8 weeksDescription: Indicate if the patient had positive serological antibodies at the end of the study
Measure: Seroconversion Time: 8 weeksDescription: Need for hospitalization independent of the level of complexity due to covid-19
Measure: Hospitalization requirement Time: 8 weeksDescription: ICU need due to Covid-19
Measure: Intensive Care Unit Requirement Time: 8 weeksDescription: Adverse effect due to medication or placebo
Measure: Safety of the intervention Time: 8 weeksIt is a single-center, prospective, randomized, double-blind, placebo-controlled study carried out by the Ministry of Public Health of the Province of Corrientes, Argentina, in coordination with the Corrientes Institute of Cardiology "Juana F. Cabral". Patients who meet all the inclusion criteria and none of the exclusion criteria are randomized via the web system to receive placebo or ivermectin. The need for hospitalization in patients with COVID-19 is assessed as the primary end point. As secondary end points are evaluated: time to hospitalization (in days); use of invasive mechanical ventilation; time to invasive mechanical ventilation (in days); dialysis; all-cause mortality; negative of the swab at 3 ± 1 days and 12 ± 2 days after entering the study and ivermectin safety. Intermediate internal analyzes of study objectives and serious adverse events will be performed, including 125; 250 and 375 patients in order to assess the possible need for early termination of the study. For these intermediate internal analyzes, the Haybittle-Peto rule will be followed, therefore a value of p <0.001 will be considered significant
Description: Hospitalization will be considered when at least 24 hours have elapsed in a health institution, in any of its services.
Measure: Percentage of Hospitalization of medical cause in patients with COVID-19 in each arm Time: through study completion, an average of 30 daysDescription: Number of days elapsed
Measure: Time to hospitalization Time: through study completion, an average of 30 daysDescription: All patients who are connected to invasive mechanical ventilation support
Measure: Percentage of Use of invasive mechanical ventilation support in each arm Time: through study completion, an average of 30 daysDescription: Number of days elapsed
Measure: Time to invasive mechanical ventilation support Time: through study completion, an average of 30 daysDescription: All patients who require temporary or permanent renal replacement therapy
Measure: Percentage of dialysis in each arm Time: through study completion, an average of 30 daysDescription: Death of the patient, from any cause.
Measure: All-cause mortality Time: through study completion, an average of 30 daysDescription: Negative Nasal Swab Using Polymerase Chain Reaction Technique
Measure: Negative of the swab at 3±1 days and 12±2 days after entering the study Time: At days 3±1 and 12±2Description: According to the adverse events that patients may present.
Measure: Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]) Time: through study completion, an average of 30 daysSince the onset of the disease, more than 40.5 million people have been diagnosed with COVID-19 and nearly 1.2 million people have died (October 21, 2020). There is no complete understanding of the pathogenesis of SARS-CoV-2 infection and to this day there is no specific therapy or vaccine available. Thus, patient care is based on symptomatic therapy and treatment of complications. Ivermectin has been used for more than 30 years for the treatment of several diseases. More than one million doses of the drug are administered daily, particularly in low- and middle-income countries. Due to the low prevalence of adverse events with the use of this drug, ivermectin is considered to have a good safety profile and its potential benefit in other diseases is currently under investigation. An in vitro study of ivermectin in SARS-CoV-2 in Australia showed a significant reduction of viral load in infected cells. Subsequently, a descriptive study of 704 critical patients with COVID-19 showed a reduction in mortality, hospitalization, and intensive care unit length-of-stay in those patients who received the drug. Unfortunately, this study was withdrawn by its authors, leaving more questions than answers. Some countries in Latin America have authorized its use for the management of patients with COVID-19 even in the absence of solid evidence, and several other countries are conducting clinical trials to evaluate its efficacy for the treatment of moderate and severe disease. Since there is no specific treatment for COVID-19 and the therapeutic options are scarce, the researchers believe it is completely plausible, urgent, and necessary to evaluate if ivermectin use reduces the risk of admission to an intensive care unit (ICU) in hospitalized adults with severe COVID-19. The proposal is a randomized, double-blind clinical trial, conducted at CES Clinic, Medellin-Colombia. The investigators will randomize 100 patients with severe, non-critical illness, into two groups, one group will receive ivermectin in addition to standard management and the other group will receive placebo plus standard management. Clinical outcomes to evaluate will be ICU admission, need for mechanical ventilation, length of hospital stay, days in the ICU and mechanical ventilation, and finally, the incidence of adverse events related to the intervention. The estimated time to complete the study is approximately five months.
Description: Cumulative incidence of ICU admission.
Measure: Admission to the intensive care unit. Time: 21 daysDescription: Duration of hospitalization (days).
Measure: Hospital length of stay. Time: 21 daysDescription: 21-day mortality.
Measure: Mortality rate. Time: 21 daysDescription: Number of days in ICU.
Measure: ICU length of stay. Time: 21 daysDescription: Number of days with mechanical ventilator.
Measure: Length of stay in ventilator time. Time: 21 daysDescription: Cumulative incidence of adverse effects: headache, rash, pruritus, arthralgia, tachycardia, dizziness, hypotension, uveitis, Steven Johnson Syndrome.
Measure: Adverse effects of ivermectin. Time: 21 daysAn early stage trial to check how safe and tolerable, as well as how the body handles continuous daily use of Active IMP over 28 days in healthy volunteers to help with coronavirus infection (COVID-19).
Description: Maximum plasma concentration (Cmax)
Measure: Pharmacokinetic concentrations - (Maximum Plasma Concentration [Cmax]) Time: Study day 42 (at 14 days post the final dose)Description: Time to reach Cmax (tmax)
Measure: Pharmacokinetic concentrations - (Time to Reach Cmax [Tmax]) Time: Study day 42 (at 14 days post the final dose)Description: trough plasma concentration (Ctrough)
Measure: Pharmacokinetic concentrations - (Trough Plasma Concentration [Ctrough]) Time: Study day 42 (at 14 days post the final dose)Description: area under the plasma concentration-time curve from zero to 24 hours (AUC0-24h) concentration-time curve from zero to 24 hours (AUC0-24h)
Measure: Pharmacokinetic concentrations - (Area under the plasma concentration-time curve from zero to 24 hours [AUC0-24h]) Time: Study day 42 (at 14 days post the final dose)Description: area under the plasma concentration-time curve from zero to 48 hours (AUC0-48h)
Measure: Pharmacokinetic concentrations - (Area under the plasma concentration-time curve from zero to 48 hours [AUC0-48h]) Time: Study day 42 (at 14 days post the final dose)Description: average plasma concentration at steady state (Cavg ss)
Measure: Pharmacokinetic concentrations - (Average Plasma Concentration at steady state [Cavg ss]) Time: Study day 42 (at 14 days post the final dose)Description: apparent terminal half-life (t1/2)
Measure: Pharmacokinetic concentrations - (Apparent Terminal Half-Life [T1/2]) Time: Study day 42 (at 14 days post the final dose)Description: Clinical safety data from adverse event (AE) reporting
Measure: Safety and Tolerability - Number of participants with treatment emergent adverse events (TEAEs) Time: Study day 42 (at 14 days post the final dose)Description: Assessment of cardiac electrical activity
Measure: Safety and Tolerability - Number of participants with abnormal electrocardiograms (ECG) Time: Study day 42 (at 14 days post the final dose)Description: Assessment of neurological function
Measure: Safety and Tolerability - Number of participants with abnormal clinical neurological exam, as assessed by the investigator Time: Study day 42 (at 14 days post the final dose)Description: Assessment of clinical laboratory results
Measure: Safety and Tolerability - Number of participants with abnormal urine and/or blood test, as compared to reference laboratory values Time: Study day 42 (at 14 days post the final dose)Description: Assessment of physical examination results
Measure: Safety and Tolerability - Number of participants with abnormal physical exams, as assessed by the investigator Time: Study day 42 (at 14 days post the final dose)SAINT-PERU is a triple-blind, randomized controlled trial with two parallel groups to compare the efficacy of ivermectin versus placebo to obtain negative PCR results in patients with early phase COVID-19. The trial is currently planned at a single center in Lima.
Description: Proportion of patients with a positive SARS-CoV-2 PCR from a nasopharyngeal swab at day 7 post-treatment
Measure: Proportion of patients with a positive SARS-CoV-2 PCR. Time: 7 days post-treatmentDescription: Change from baseline quantitative and semi-quantitative PCR in nasopharyngeal swab
Measure: Mean viral load Time: Baseline and on days 4, 7, 14 and 21Description: Proportion of patients with fever and cough at days 4, 7, 14 and 21 as well as proportion of patients progressing to severe disease or death during the trial
Measure: Fever and cough progression Time: Up to and including day 21Description: Proportion of participants with positive IgG at day 21
Measure: Seroconversion at day 21 Time: Up to and including day 21Description: Proportion of drug-related adverse events
Measure: Proportion of drug-related adverse events Time: 7 days post treatmentDescription: Frequency (% over total PBMC) of innate immune cells (myeloid and plasmacytoid dendritic cells, NK cell, classical, intermediate and pro-inflammatory macrophages) measured in cryopreserved PBMC by flow cytometry
Measure: Frequency of innate immune cells Time: Up to and including day 7Description: Frequency of CD4+ T and CD8+ T cells (% over total CD4+T and CD8+ T) expressing any functional marker upon in vitro stimulation of PBMC with SARS-CoV-2 peptides, measured by flow cytometry
Measure: Frequency SARS-CoV-2-specific CD4+ T and and CD8+ T cells Time: Up to and including day 7Description: Concentration (all in pg/mL) of epidermal growth factor (EGF), fibroblast growth factor (FGF), granulocyte colony-stimulating factor (G-CSF), granulocyte-macrophage colony-stimulating factor (GM-CSF), hepatocyte growth factor (HGF), vascular endothelial growth factor (VEGF), tumour necrosis factor (TNF), interferon (IFN)-α, IFN-γ, interleukin (IL)-1RA, IL-1β, IL-2, IL-2R, IL-4, IL-5, IL-6, IL-7, IL-8, IL-10, IL-12(p40/p70), IL-13, IL-15, IL-17, IFN-γ induced protein (IP-10), monocyte chemoattractant protein (MCP-1), monokine induced by IFN-γ (MIG), macrophage inflammatory protein (MIP)-1α, MIP-1β in plasma measured by a Luminex assay using a commercially available kit (Cytokine Human Magnetic 30-Plex Panel from ThermoFisher)
Measure: Results from cytokine Human Magnetic 30-Plex Panel Time: Up to and including day 21Description: Proportion and parasitic load of intestinal helminths by quantitative Kato-katz and Baerman method
Measure: Presence of intestinal helminths Time: Baseline and on day 14.In this multicenter study; it was aimed to investigate the effectiveness and safety of ivermectin use in the treatment of patients with severe COVID-19 pneumonia that have no mutations which alter ivermectin metabolism and cause side effects.
Description: The gender of patients (Male/female) in both groups were recorded at the time of inclusion.
Measure: Gender distribution of the patients Time: At the first day of the studyDescription: The age of the patients (years) in both groups were recorded at the time of inclusion.
Measure: Age distribution of the patients Time: At the first day of the studyDescription: At the beginning of the study, the patients were asked whether there were any of the following accompanying diseases and the percentage of patients with accompanying disease in both groups were recorded: Diabetes mellitus Hypertension Coronary artery disease Cardiac failure Chronic obstructive pulmonary disease Malignancy Immunodeficiency
Measure: Percentage of patients with accompanying diseases Time: At the first day of the studyDescription: At the beginning of the study, the patients were asked whether there were any of the following clinical symptoms and the percentage of patients with any of the clinical symptoms in both groups were recorded: Fever Cough Sore throat Dispnea Headache Weakness Myalgia Diarrhea Nausea or vomiting
Measure: Percentage of patients with baseline clinical symptoms Time: At the first day of the studyDescription: At the beginning of the study, the body temperatures (as degree celcius) of the patients were measured and the mean body temperature values of both groups were recorded.
Measure: Body temperature means of the patients Time: At the first day of the studyDescription: At the beginning of the study, the heart rates (as per minute) of the patients were measured and the mean heart rate values of both groups were recorded.
Measure: Heart rate means of the patients Time: At the first day of the studyDescription: At the beginning of the study, the respiratory rates (as per minute) of the patients were measured and the mean respiratory rate values of both groups were recorded.
Measure: Respiratory rate means of the patients Time: At the first day of the studyDescription: At the beginning of the study, the systolic and diastolic pressures (as mmHg) of the patients were measured and the mean systolic and diastolic pressure values of both groups were recorded.
Measure: Systolic and diastolic pressure means of the patients Time: At the first day of the studyDescription: The presence of at least two of the following criteria in patients at the end of 5th day were accepted as "clinical response": Extubation in mechanically ventilated patients, respiratory rate <26/min, SpO2 level in room air >90%, PaO2/FiO2 >300 in patients receiving oxygen, presence of at least two of the 2-point reduction criteria in "Sequential Organ Failure Assessment (SOFA)" score.
Measure: Clinical response Time: From starting to the end of ivermectin therapy (0 to the end of 5th day)Description: The SpO2 values (as %) of the patients in both groups were recorded at the beginning and every 24 hours.
Measure: Changes in oxygen saturation (SpO2) values Time: From starting to the end of ivermectin therapy (0 to the end of 5th day)Description: The ratio of PaO2/FiO2 values of the patients in both groups were recorded at the beginning and every 24 hours.
Measure: Changes in the ratio of partial pressure of oxygen (PaO2) to fraction of inspired oxygen (FiO2) (PaO2/FiO2) Time: From starting to the end of ivermectin therapy (0 to the end of 5th day)Description: Serum Lymphocyte counts (cell/mm3) of the patients in both groups were recorded at the beginning and every 24 hours.
Measure: Changes in serum lymphocyte counts Time: From starting to the end of ivermectin therapy (0 to the end of 5th day)Description: PNL/L ratio of the patients in both groups were recorded at the beginning and every 24 hours.
Measure: Changes in the ratio of polymorphonuclear leukocyte count to lymphocyte count (PNL/L) Time: From starting to the end of ivermectin therapy (0 to the end of 5th day)Description: Serum ferritin levels (mg/dL) of the patients in both groups were recorded at the beginning and every 24 hours.
Measure: Changes in serum ferritin levels Time: From starting to the end of ivermectin therapy (0 to the end of 5th day)Description: Serum D-dimer levels (mg/L) of the patients in both groups were recorded at the beginning and every 24 hours.
Measure: Changes in serum D-dimer levels Time: From starting to the end of ivermectin therapy (0 to the end of 5th day)Description: A blood sample was taken from the patients included in the study group, after taking or during the first dose of ivermectin. From the blood samples, haplotypes and mutations that cause the function losing were investigated by performing sequence analysis of multidrug resistance 1 (MDR1)/ABCB1 and CYP3A4 genes with Sanger method. In case of detection of mutation, the patient were excluded from the study and if observed, side effects of ivermectin were noted.
Measure: Genetic examination of haplotypes and mutations that cause function losing for ivermectin metabolism Time: At the first day of ivermectin therapy (1st day)Description: Adverse effects of ivermectin and drugs other than ivermectin (Hydroxychloroquine, favipiravir, azithromycin) were evaluated in the patients in the study group and and the number of participants were noted. Adverse effects of drugs other than ivermectin (Hydroxychloroquine, favipiravir, azithromycin) were evaluated in the patients in the control group and and the number of participants were noted.
Measure: Treatment-Related Adverse Events as Assessed by CTCAE v4.0 Time: At the first 5 days of studyDescription: The presence of at least two of the following criteria in patients on the 10th day were accepted as "clinical response": Respiration rate between 22-24/min, SpO2 level in room air >95%, absence of oxygen requirement, observation of radiological improvement in control lung tomography and no need for intensive care.
Measure: Clinical response Time: 10 days (5 days ivermectin therapy plus 5 days follow-up)Description: The number of died patients were evaluated in study and control groups
Measure: Mortality Time: Through study completion, an average of 3 monthsDescription: The SpO2 values (as %) of the patients in both groups were recorded at the every 24 hours.
Measure: Changes in oxygen saturation (SpO2) values Time: From 6th to the end of 10th dayDescription: The PaO2/FiO2 values of the patients in both groups were recorded at the every 24 hours.
Measure: Changes in the ratio of partial pressure of oxygen (PaO2) to fraction of inspired oxygen (FiO2) (PaO2/FiO2) Time: From 6th to the end of 10th dayDescription: Serum Lymphocyte counts (cell/mm3) of the patients in both groups were recorded at the every 24 hours.
Measure: Changes in serum lymphocyte counts Time: From 6th to the end of 10th dayDescription: PNL/L ratio of the patients in both groups were recorded at the every 24 hours.
Measure: Changes in the ratio of polymorphonuclear leukocyte count to lymphocyte count (PNL/L) Time: From 6th to the end of 10th dayDescription: Serum ferritin levels (mg/dL) of the patients in both groups were recorded at the every 24 hours.
Measure: Changes in serum ferritin levels Time: From 6th to the end of 10th dayDescription: Serum D-dimer levels (mg/L) of the patients in both groups were recorded at the every 24 hours.
Measure: Changes in serum D-dimer levels Time: From 6th to the end of 10th dayDescription: At the end of the follow-up period (10th day), patients in the study and control group were investigated by PCR test for SARS-CoV-2 and the negative results were recorded as percentage for both groups.
Measure: Rate of COVID-19 Polymerase Chain Reaction (PCR) test negativity Time: At the end of 10th dayDescription: Adverse effects of ivermectin and drugs other than ivermectin (Hydroxychloroquine, favipiravir, azithromycin) were evaluated in the patients in the study group and and the number of participants were noted. Adverse effects of drugs other than ivermectin (Hydroxychloroquine, favipiravir, azithromycin) were evaluated in the patients in the control group and and the number of participants were noted.
Measure: Treatment-Related Adverse Events as Assessed by CTCAE v4.0 Time: From the 6th day of study to the 10th day of studyBackground: Up-to-date, there is no recognized effective treatment or vaccine for the treatment of coronavirus disease (COVID-19) that emphasize urgency around distinctive effective therapies. This study aims to evaluate the anti-parasitic medication efficacy "Ivermectin" plus standard care (Azithromycin, Paracetamol, vitamin C, Zinc, Lactoferrin, Acetylcystein, prophylactic or therapeutic anticoagulation if D-dimer > 1000 and/or steroids) in the treatment of mild/moderate and severely ill cases with COVID 19 infection versus Hydroxychloroquine plus standard care, as well as Ivermectin prophylaxis of health care and/ or household contacts. Subject and methods: 600 subjects; 400 symptomatic confirmed COVID-19 patients and 200 health care and household contacts distributed over 6 groups; Group I: 100 patients with Mild/Moderate COVID-19 infection received a 4-days course of Ivermectin plus standard care; Group II: 100 patients with mild/moderate COVID-19 infection received hydroxychlorquine plus standard care; Group III: 100 patients with severe COVID-19 infection received Ivermectin plus standard of care; Group IV: 100 patients with Severe COVID-19 infection received hydroxychlorquine plus standard care. Routine laboratory investigations and real time- polymerase chain reaction (rt-PCR) were reported before and after initiation of treatment. Group V stick to personal protective equipment (PPE) plus Ivermectin, and Group VI stick to PPE only and both groups were followed for two weeks.
Description: improvement of dyspnea using mMRC scale, disappearance of fever using thermometer, Fatigue using Fatigue Assessment Scale (FAS), and improvement of Oxygen saturation using pulse oximeter.
Measure: number of participants with improvement of clinical condition (symptoms and signs) Time: 3 monthsDescription: recording days of clinical improvement (recovery time) , hospital stay days and mortality rate
Measure: Reduction of recovery time, hospital stay days and mortality rate Time: 3 monthsDescription: improvement of laboratory investigations (CBC, CRP, Ferritin, D-dimer) and 2 consecutive negative PCR tests taken at least 48 hours apart.
Measure: improvement of laboratory investigations and 2 consecutive negative PCR tests taken at least 48 hours apart. Time: 3 monthsAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on January 01, 2021.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports